Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study.
Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, Bacher U, Staber P, Mazzeo P, Leng C, Böckle D, Hölscher A, Kauer J, Rotter N, Vucinic V, Rudzki J, Nachbaur D, Bücklein V, Schnetzke U, Krämer I, Wille K, Hasse A, von Tresckow B, Hänel M, Koenecke C, Velazquez GF, Viardot A, Schmid C, Thurner L, Wolf D, Subklewe M, Dreyling M, Dreger P, Dietrich S, Keller U, Jäger U, Greil R, Pabst T, Lenz G, Chapuy B.
Shumilov E, et al. Among authors: melchardt t.
Blood Adv. 2025 Aug 12;9(15):3865-3877. doi: 10.1182/bloodadvances.2024014903.
Blood Adv. 2025.
PMID: 39661985
Free PMC article.